A recent study conducted in Japan has shown that the weight loss Acomplia can help to significantly reduce levels of visceral fat in humans. Visceral fat is the fat that collects around the abdomen, where vital internal organs are present. This is the most dangerous type of extra fat that a person can carry. Visceral fat is also called metabolically active fat. It collects around the liver and pancreas and is a leading contributor to disease.
The Japanese study results were announced at a meeting of the Association for the Study of Diabetes in Europe. Researchers examined the two types of fat that accumulates in the body, visceral fat and subcutaneous fat (the type that accumulates under the skin). It was explained that when visceral fat accumulates, insulin resistance, type 2 diabetes, and cardio metabolic disease can result.
More than five hundred significantly overweight men and women took part in a study of the effects of Acomplia on visceral fat. At the end of the study, the subjects who took Acomplia according to a regular dosing schedule had lost much more visceral fat than those who took a placebo pill.
The manufacturer of Acomplia, Sanofi Aventis, is attempting to position Acomplia as more than a weight loss drug. The company says that drug Acomplia can also help to improve metabolic conditions, including diabetes. If they are successful in getting it recognized in this way, Acomplia may soon be seen more as a medication and less as a cosmetic pill. In fact, the new findings about Acomplia may help get it approved for use in hospitals.
At the present time, Acomplia is known mostly as a weight loss aid. It works by interfering with hunger signals from the brain, which causes suppression of appetite. You can buy Acomplia online in the United Kingdom for more than a year. Acomplia is available in most of Europe by prescription.
